Our approach takes advantage of state-of-the-art post-genomic era technologies, utilising molecular profiling methods and computational analysis in an unbiased manner to gather data and generate novel hypotheses. Over the last 15 years, the Bahn group has completed the most extensive 'omics' study (transcriptomics, metabolomics and proteomics) to date on post mortem brain tissue from more than 150 subjects and has developed new scientific hypotheses relating to the pathophysiology of schizophrenia, bipolar affective disorder, and other neuropsychiatric conditions. Following this achievement our research focus has moved to the identification of biomarkers/surrogate markers in accessible tissues such as blood and cerebrospinal fluid, in order to test these hypotheses in patients and to identify biomarkers with diagnostic and therapeutic value. We have established a centre of technological excellence in the field of "-omics"-based biomarker research and the group now includes more than 20 scientists with strong scientific, bioinformatics and computing skills.
Our research is patient-focused, always keeping in mind the clear aim of improving the treatment and outcome of these devastating disorders.
The goals of the Bahn laboratory are to develop molecular diagnostics for neuropsychiatric disorders, to establish and test new hypotheses of the pathological basis to determine the cellular mechanisms which regulate the expression of biomarker molecules altered in these states, with a view to developing novel therapeutic strategies.